Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 91 Stomach Neoplasms 44 Pancreatic Neoplasms 37 Rectal Neoplasms 29 Colonic Neoplasms 23 Neoplasms 22 Esophageal Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 20 Neoplasm Metastasis 18 Cholangiocarcinoma 16 Adenocarcinoma Of Esophagus 16 Biliary Tract Neoplasms 13 Parkinson Disease 4, Autosomal Dominant Lewy Body 12 Head and Neck Neoplasms 12 Esophageal Squamous Cell Carcinoma 12 Carcinoma, Non-Small-Cell Lung 12 Adenocarcinoma 12 Urinary Bladder Neoplasms 11 Ovarian Neoplasms 9 Gastrointestinal Neoplasms 9 Carcinoma, Hepatocellular 7 Endometrial Neoplasms 6 Breast Neoplasms 6 Gallbladder Neoplasms 5 Advanced Solid Tumors 5 Uterine Cervical Neoplasms 4 Peritoneal Neoplasms 4 Lung Neoplasms 4 Carcinoma 4 Appendiceal Neoplasms 4

Interventions

Carboplatin 6 pembrolizumab 3 Paclitaxel 3 Observation 3 Capecitabine 3 Azacitidine 3 venetoclax 2 pertuzumab 2 olaparib 2 durvalumab 2 Tretinoin 2 Trastuzumab 2 Standard of Care 2 Oxaliplatin 2 Irinotecan 2 Immunotherapy 2 Chemoradiotherapy 2 130-nm albumin-bound paclitaxel 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 toripalimab 1 tislelizumab 1 tegafur-gimeracil-oteracil 1 taxane 1 talazoparib 1 tagraxofusp 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pathologic Complete Response × Fluorouracil × 1 year × Clear all

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡